• Lili Ren, Hui Guan, Guohua Dai, Wulin Gao, and Jing Su.
• First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2021 Apr 16; 100 (15): e24531e24531.

BackgroundAs the last link in the chain of cardiovascular events, chronic heart failure (CHF) has high morbidity, high mortality, and poor prognosis. It is one of the main causes of death and disability worldwide. Shenfuqiangxin Pills (SFQX) is widely used as a Chinese herbal medicine (CHM) prescription for CHF, but there is still a lack of strict evidence-based medical evidence. Therefore, we make a protocol for evaluating the efficacy and safety of SFQX for CHF.MethodsAccording to the search strategy, randomized controlled trials (RCTs) of SFQX for CHF will be retrieved from 8 databases without limitation of publication date or language. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using software for traditional meta-analysis. Finally, using GRADE method to assess the strength of recommendations.ResultsThis study will evaluate the efficacy and safety of SFQX for CHF, thereby providing more evidence support for clinical decision-making in CHF.ConclusionOur research will provide more references for the clinical medication of patients with CHF.Protocol Registration NumberINPLASY202110019.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…